{
    "clinical_study": {
        "@rank": "109189", 
        "acronym": "cardiohcs", 
        "arm_group": [
            {
                "arm_group_label": "Congenital adrenal hyperplasia", 
                "description": "Patients > 18 yrs with classical or non classical CAH diagnosed during childhood"
            }, 
            {
                "arm_group_label": "controls", 
                "description": "control patients"
            }
        ], 
        "biospec_descr": {
            "textblock": "serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal\n      hyperplasia (CAH) from a fatal to a chronic lifelong disease. Long-term treatment, in\n      particular the chronic (over-)treatment with glucocorticoids, may have an adverse effect on\n      the cardiovascular risk profile in adult CAH patients. The objective of this study was to\n      evaluate the cardiovascular risk profile of adult CAH patients."
        }, 
        "brief_title": "Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Congenital Adrenal Hyperplasia", 
        "condition_browse": {
            "mesh_term": [
                "Adrenal Hyperplasia, Congenital", 
                "Adrenogenital Syndrome", 
                "Adrenocortical Hyperfunction", 
                "Hyperplasia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal\n      hyperplasia (CAH) from a fatal to a chronic lifelong disease. Long-term treatment, in\n      particular the chronic (over-)treatment with glucocorticoids, may have an adverse effect on\n      the cardiovascular risk profile in adult CAH patients. The objective of this study was to\n      evaluate the cardiovascular risk profile of adult CAH patients.\n\n      DESIGN: Case control study Primary objective : detection of cardiovascular damage in\n      patients with classical or non classical CAH diagnosed in childhood. The patients will be\n      compared with age- and gender- and tobacco status- matched control.\n\n      Secondary objective Study of microvascular function Evaluation of cardiovascular risk\n      factors Total cumulative (TCG) and total average (TAG) glucocorticoid doses will be\n      calculated from pediatric and adult files and correlated to arterial macro- and\n      microcirculatory dysfunction.\n\n      Primary outcome Ultrasound evaluation of intima-media thickness at common carotids, carotid\n      bulbs and left ventricular function Secondary outcome Peripheral and central blood pressure\n      Skin capillary density and pulse-wave velocity Glucose and insulin during an oral glucose\n      tolerance test Circulating cardiovascular risk markers (hsCRP, adiponectin, Interleukin-6)\n      Lipid profile Anthropometry, fat and lean mass measured by dual-energy X-ray absorptiometry\n      Total cumulative dose of glucocorticoid Number of subjects : 90 patients/90 controls\n      Inclusion criteria of CAH patients\n\n        -  Patients > 18 yrs with classical or non classical CAH diagnosed during childhood\n\n        -  Absence of known cardiovascular disease\n\n        -  Absence of combined oral contraceptives during the previous month Inclusion criteria of\n           controls\n\n        -  Age under 18\n\n        -  Absence of known cardiovascular disease\n\n        -  Absence of combined oral contraceptives during the previous month\n\n      Duration of the inclusion period: 3 years"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria : patients\n\n          -  Patients > 18 yrs with classical or non classical CAH diagnosed during childhood\n\n          -  Absence of known cardiovascular disease\n\n          -  Absence of combined oral contraceptives during the previous month\n\n        Inclusion criteria : controls\n\n          -  Age > 18 yrs\n\n          -  Absence of known cardiovascular disease\n\n          -  Absence of combined oral contraceptives during the previous month\n\n        Exclusion criteria :\n\n          -  Blood donation during the previous 3 months\n\n          -  Cardiovascular disease\n\n          -  Treatment by combined oral contraceptives\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients > 18 yrs with classical or non classical CAH diagnosed during childhood and\n        controls"
            }
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807364", 
            "org_study_id": "AOR 10032", 
            "secondary_id": "P091106"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epinephrine", 
                "Epinephryl borate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Congenital adrenal hyperplasia (CAH)", 
            "Cardiovascular risk", 
            "Microvascular dysfunction"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "contact": {
                "last_name": "Anne Bachelot", 
                "phone": "00 33 1 42 16 02 46"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75013"
                }, 
                "name": "Piti\u00e9 Salp\u00eatri\u00e8re Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "2", 
        "official_title": "Evaluation of Cardiovascular Risk Profile in Adult Patients With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency Diagnosed During Childhood", 
        "overall_contact": {
            "email": "anne.bachelot@psl.aphp.fr", 
            "last_name": "Anne Bachelot, Md, PhD"
        }, 
        "overall_official": {
            "affiliation": "APHP", 
            "last_name": "Anne Bachelot, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs and left ventricular function", 
            "measure": "Ultrasound evaluation of intima-media thickness", 
            "safety_issue": "No", 
            "time_frame": "day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807364"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Peripheral", 
                "measure": "Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Skin capillary density", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Insulin during an oral glucose tolerance test", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "description": "Interleukin-6", 
                "measure": "Circulating cardiovascular risk markers", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Lipid profile", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Lean mass measured by dual-energy X-ray absorptiometry", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "description": "Calculated from pediatric and adult files", 
                "measure": "Total cumulative dose of glucocorticoid will be calculated from pediatric and adult files", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Pulse-wave velocity", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Glucose during an oral glucose tolerance test", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Anthropometry measured by dual-energy X-ray absorptiometry", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "measure": "Fat measured by dual-energy X-ray absorptiometry", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "description": "Central", 
                "measure": "Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "description": "hsCRP", 
                "measure": "Circulating cardiovascular risk markers", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }, 
            {
                "description": "adiponectin", 
                "measure": "Circulating cardiovascular risk markers", 
                "safety_issue": "No", 
                "time_frame": "day 1"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}